Published Date: 08 Mar 2023
A groundbreaking study by the University of Bristol and the University of Essex has revealed new insights into the importance of early childhood for lung health.
Read Full NewsImmune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.
As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.
Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.
1.
Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer
2.
In Acute Leukemia With Heavily Pretreated Patients, Menin Inhibitor Yields 63 Percent ORR.
3.
Unexplained CAR-T Death; Americans Spurn Sunscreen; Improving Diversity in Trials
4.
In inflammatory breast cancer, ER beta regulates estrogen signaling.
5.
One-third of childhood cancer survivors experience significant fear that it could come back, study reveals
1.
Uncovering Breast Cancer: The Power of Early Stage Ultrasound
2.
What Is Gastrinoma? Understanding This Rare Tumor and Its Treatment Options
3.
Survivin as a Key Regulator in Gynecological Cancers: Therapeutic and Prognostic Implications
4.
The Mystery of Carotid Body Tumors: The Facts You Need to Know
5.
The Mysterious World of Petechiae: Exploring Causes and Treatments
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Oropharyngeal Cancer in Relation to HPV Status
3.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
4.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation